Clopidogrel bisulfate 75 mg
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Clopidogrel Bisulfate 75 mg: Bioequivalence, Efficacy, and Safety
Bioequivalence of Clopidogrel Bisulfate Formulations
Comparative Bioavailability Studies
Several studies have evaluated the bioequivalence of different formulations of clopidogrel bisulfate 75 mg tablets. A study comparing a generic clopidogrel bisulfate formulation to the reference product, Plavix®, found no significant differences in pharmacokinetic parameters such as AUC and Cmax, with values falling within the bioequivalence range of 80%-125% specified by regulatory agencies. Another study confirmed the bioequivalence of a new generic product with the originator product, showing similar AUC and Cmax values.
Pharmacokinetic and Pharmacodynamic Comparisons
Research comparing clopidogrel bisulfate with other clopidogrel salt preparations, such as clopidogrel besylate, demonstrated no significant differences in pharmacokinetic parameters or antiplatelet effects. Both formulations met the regulatory requirements for bioequivalence and were well tolerated . Additionally, a study comparing clopidogrel bisulfate with clopidogrel napadisilate in stroke patients found that both formulations had similar efficacy and safety profiles, confirming the non-inferiority of clopidogrel napadisilate.
Efficacy in Reducing Atherothrombotic Events
Clinical Trials in STEMI Patients
Clopidogrel bisulfate is widely used to reduce atherothrombotic events in patients with ST-segment elevation myocardial infarction (STEMI). In the COMMIT/CCS-2 trial, clopidogrel 75 mg/day plus aspirin significantly reduced the risk of reinfarction, stroke, or death compared to aspirin alone. Treating 1000 patients for approximately two weeks with clopidogrel resulted in nine fewer deaths, reinfarctions, or strokes. The CLARITY-TIMI 28 trial also supported these findings, showing that clopidogrel plus aspirin reduced the odds of occluded infarct-related arteries, recurrent myocardial infarction, or death compared to aspirin plus placebo.
Efficacy in Other Patient Populations
Long-term clopidogrel monotherapy has been shown to be generally well tolerated in patients with recent myocardial infarction, ischemic stroke, or established peripheral arterial disease, further supporting its efficacy in reducing atherothrombotic events.
Safety and Tolerability
Adverse Events and Safety Profiles
Studies have consistently shown that clopidogrel bisulfate is well tolerated. In clinical trials, the rate of major bleeding was not significantly different between clopidogrel and control groups. Comparative studies with other clopidogrel formulations, such as clopidogrel besylate and clopidogrel napadisilate, also reported similar safety profiles, with no significant differences in adverse events .
Quality Control and Manufacturing Standards
Quality control testing of clopidogrel bisulfate tablets marketed in Iraq confirmed that all batches met the USP pharmacopeia standards for weight variation, hardness, friability, disintegration time, and drug content. These tests ensure the effectiveness and safety of the tablets.
Conclusion
Clopidogrel bisulfate 75 mg is a bioequivalent, effective, and safe option for reducing atherothrombotic events in various patient populations. Comparative studies with other clopidogrel formulations have confirmed its efficacy and tolerability, making it a reliable choice for long-term antiplatelet therapy.
Sources and full results
Most relevant research papers on this topic